CXCR3 and neoplasm: Very recently Andy Luster and his group showed that anti PD-1 efficacy is reduced in CXCR3KO mice, and suggested that the interaction between CXCL9, largely produced by CD103+ dendritic cells (DC) at the tumor site, and CXCR3 on CD8+ T cells enhances anti PD-1 efficacy (7).